China's BeiGene, Merck KGaA Expand Cancer-Drug Partnership
This article was originally published in PharmAsia News
Executive Summary
BeiGene and Merck KGaA have signed an agreement to develop the China biotech's BeiGene-290 cancer drug, expanding a partnership that began earlier this year with two other BeiGene cancer treatments.